CD81 is co-opted during the life cycle of diversehuman pathogens: it is involved in hepatitis C virus (HCV) andPlasmodium sporozoite invasion of hepatocytes, and alsocontributes to the assembly and budding of human immunodeficiencyvirus and influenza A virus. Developed as a part of panel of murine monoclonalantibodies against full-length CD81 to further examine and assessed their […]
| Institute |
|---|
| University of Birmingham |
| Cat. #: | 154243 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Immunology;Microbiology |
| Application: | WB ; ELISA ; FACS ; IF |
| Target: | CD81 and its second extracellular domain (EC2) |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | 26 kDa cell surface protein TAPA-1,Target of the antiproliferative antibody 1, Tetraspanin-28 |
|---|---|
| Product description: | CD81 is co-opted during the life cycle of diversehuman pathogens: it is involved in hepatitis C virus (HCV) andPlasmodium sporozoite invasion of hepatocytes, and alsocontributes to the assembly and budding of human immunodeficiencyvirus and influenza A virus. Developed as a part of panel of murine monoclonalantibodies against full-length CD81 to further examine and assessed their ability to inhibit or neutralize HCV infection. |
| Conjugation: | Unconjugated |
| Immunogen: | P60033, CD81_HUMAN |
| Immunogen Uniprot ID: | P60033, CD81_HUMAN |
| Myeloma used: | NS0 |
| Target background: | CD81 is co-opted during the life cycle of diversehuman pathogens: it is involved in hepatitis C virus (HCV) andPlasmodium sporozoite invasion of hepatocytes, and alsocontributes to the assembly and budding of human immunodeficiencyvirus and influenza A virus. Developed as a part of panel of murine monoclonalantibodies against full-length CD81 to further examine and assessed their ability to inhibit or neutralize HCV infection. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Tkachuk et al. 1975. FEBS Lett. 52(1):66-8. PMID: 1123084. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.